Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis

Inflammatory Bowel Diseases

Volumn 11, Issue 2, 2005, Pages 106-115

  Aharoni, Rina ^a   Kayhan, Basak ^a   Arnon, Ruth ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Crohn's disease; Immunomodulation; Inflammatory bowel diseases

Indexed keywords

GLATIRAMER; TRANSFORMING GROWTH FACTOR BETA; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; IMMUNOSUPPRESSIVE AGENT; PEPTIDE; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; ANIMAL; ANIMAL DISEASE; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; CROHN DISEASE; DISEASE MODEL; HOSPITALIZATION; MULTIPLE SCLEROSIS; SURVIVAL;

ANIMALS; COLITIS; CROHN DISEASE; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; MULTIPLE SCLEROSIS; PEPTIDES; POLYMERS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRINITROBENZENESULFONIC ACID;

EID: 18244372722     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200502000-00003     Document Type: Article

References (21)

1. Shanahan F. IBD: Immunodiagnostics immunotherapeutics and ectotherapeutics. Gastroenterology. 2001;120:622-635.
2. Sandborn WJ, Targan SR. Biologic therapy of IBD. Gastroenterology. 2002;122:1592-1608.
3. Van Deventer SJH. Immunotherapy of Crohn's disease. Scand J Immunol. 2000;51:18-22.
4. Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother. 2001;2:1149-1165.
5. Fridkis-Hareli M, Teitelbaum D, Gurevich E, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - specificity and promiscuity. Proc Natl Acad Sci USA. 1994;91:4872-4876.
6. Aharoni R, Teitelbaum D, Sela M, et al. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 1997;94:10821-10826.
7. Aharoni R, Teitelbaum D, Sela M, et al. Bystander suppression of experimental autoimmune encephalomyelitis by T-cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol. 1998;91:135-146.
8. Neuhaus O, Farina C, Yassouriclis A, et al. Multiple sclerosis comparison of copolymer-1 reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper T helper 2 cells. Proc Natl Acad Sci USA. 2000;97:7452-7457.
9. Wirtz S, Neurath MF. Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of IBD. Int J Colorectal Dis. 2000;15:144-160.
10. Reuter BK, Asfaha S, Buret A, et al. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest. 1996;98:2076-2085.
11. Elson CO, Beagley KW, Sharmanov AT, et al. Hapten-induced model of murine inflammatory bowel disease mucosa immune responses and protection by tolerance. J Immunol. 1996;157:2174-2185.
12. Teitlbaum D, Arnon R, Sela M. Immunomodulation of experimental autoimmune encephalomyeliyis by oral administration of Copolymer 1. Proc Natl Acad Sci USA. 1999;96:3842-3847.
13. Lando Z, Teitelbaum D, Arnon R. Effect of cyclophosphamid on suppressor cell activity in mice unresponsive to EAE. J Immunol. 1979;123: 2156-2162.
14. Aharoni R, Teitelbaum D, Sela M, Arnon R. Induction of Th2 suppressor T cells by daily subcutaneous injection of copolymer 1. J Neuroimmunol. 1998;(Suppl 1):90.
15. Aharoni R, Yussim A, Sela M, et al. Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection. Int Pharmacol, in press.
16. Wardrop RM, Whitacre CC. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm Res. 1999;48:106-119.
17. Aharoni R, Schlegel PG, Teitelbaum D, et al. Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. Immunol Lett. 1997;58:79-87.
18. Aharoni R, Teitelbaum D, Arnon R, et al. Copolymer 1 inhibits manifestation of graft rejection. Transplantation. 2001; 27:598-605.
19. Aharoni R, Kayhan B, Eilam R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA. 2003;100:14157-14162.
20. Massague J. Transforming growth factor beta family. Ann Rev Cell Biol. 1990;6:597-646.
21. Neurath MF, Fuss I, Kelsall BL. Experimental Granulomatous colitis in mice is abrogated by induction of TGF-β-mediated oral tolerance. J Exp Med. 1996;183:2605-2616.